Robot-assisted Endoscope Market: as commercially mature robotic bronchoscopy platforms post procedure volume growth nearly three times faster than the broader robotic surgery base, they are establishing the clinical and commercial proof of concept that early-stage robotic gastrointestinal endoscopy developers are now explicitly building toward, so the bronchoscopy segment’s adoption trajectory is becoming the reference case investors and device developers use to judge how quickly magnetically controlled capsule endoscopes and tethered robotic colonoscopy platforms might follow a comparable path from early-stage development into mainstream procedural adoption.

The global robot-assisted endoscope market size was USD 826.0 Million in 2025 and is expected to register a revenue CAGR of 14.8% during the forecast period. Market revenue growth is driven by factors such as commercially mature robotic bronchoscopy platforms achieving procedure volume growth substantially faster than the broader robotic surgery base, early-stage robotic gastrointestinal endoscopy systems building on the clinical and commercial proof of concept bronchoscopy platforms have established, and continued improvement in patient comfort and tissue access relative to conventional flexible endoscopy driving physician interest in robotic alternatives. The first driving factor is commercially mature robotic bronchoscopy platforms, including Intuitive Surgical’s Ion and Johnson & Johnson’s Monarch, achieving procedure volume growth substantially faster than the broader robotic surgery base for peripheral lung lesion navigation and biopsy. Ion endoluminal procedure volume grew approximately 44% in the fourth quarter of 2025 compared with the fourth quarter of 2024, nearly three times the approximately 17% growth rate recorded for da Vinci surgical procedures over the same period, establishing robotic bronchoscopy as the most commercially validated robot-assisted endoscope category to date. The second driving factor is early-stage development of robotic gastrointestinal endoscopy systems, incorporating magnetically controlled capsule endoscopes and tethered robotic colonoscopy platforms, building explicitly on the clinical and commercial validation that robotic bronchoscopy platforms have already established. Magnetically controlled capsule endoscopes and tethered robotic colonoscopy platforms remain in earlier-stage development and adoption relative to robotic bronchoscopy, but they offer improved patient comfort and tissue access compared to conventional flexible endoscopy, addressing genuine clinical and patient experience limitations of conventional technique. The third driving factor is continued improvement in patient comfort and tissue access relative to conventional flexible endoscopy, driving physician and patient interest in robotic gastrointestinal endoscopy alternatives specifically. These are some of the key factors driving revenue growth of the market.

A second layer of demand comes from the way robotic bronchoscopy’s established clinical and commercial track record widens the addressable investment and development case for adjacent robot-assisted endoscope categories, letting the proof of concept one anatomical application has already validated lower the perceived clinical and commercial risk of developing robotic technology for a different, but mechanistically related, endoscopic application. Once robotic bronchoscopy demonstrates sustained procedure volume growth and clinical adoption at scale, that track record provides device developers and investors evaluating robotic gastrointestinal endoscopy technology with a concrete, comparable reference case for how quickly a genuinely novel robot-assisted endoscope category can move from early clinical use into mainstream procedural adoption, so bronchoscopy’s validated adoption trajectory directly lowers the perceived development risk for adjacent robot-assisted endoscope categories. As a result, demand and investment are concentrating around robot-assisted endoscope developers who can point to bronchoscopy’s adoption trajectory as a reference case, and the forecast tilts toward continued robotic gastrointestinal endoscopy development activity building on this established precedent rather than the category remaining a purely speculative technology bet. For instance, in the fourth quarter of 2025, Ion endoluminal procedure volume grew approximately 44% compared with the fourth quarter of 2024, a growth rate that robotic gastrointestinal endoscopy developers now cite as evidence that robot-assisted endoscopic navigation technology can achieve genuine mainstream procedural adoption once clinical utility is established, directly informing investment and development decisions in the earlier-stage magnetically controlled capsule endoscope and tethered robotic colonoscopy categories. These are some of the key factors driving revenue growth of the market.

The clearest driver of demand is the outsized procedure volume growth robotic bronchoscopy platforms are achieving, establishing the most commercially mature and clinically validated example of robot-assisted endoscope technology to date. Peripheral lung lesion navigation and biopsy addresses a distinct clinical need that conventional bronchoscopy struggles to reach reliably given the branching, narrowing anatomy of the peripheral bronchial tree, and shape-sensing and electromagnetic navigation technology directly addresses this navigational challenge, which is why robotic bronchoscopy has achieved faster clinical adoption than broader robotic surgical resection technology. Ion endoluminal procedure volume grew approximately 44% in the fourth quarter of 2025 compared with the fourth quarter of 2024, according to Intuitive Surgical’s reported results, compared with approximately 17% growth for da Vinci surgical procedures over the same period. The effect on the market is that robotic bronchoscopy has established a commercially validated adoption trajectory that the broader robot-assisted endoscope category, including earlier-stage gastrointestinal applications, is now measured against. These are some of the key factors driving revenue growth of the market.

The second driver is the way robotic bronchoscopy’s established track record is directly informing and de-risking development investment in robotic gastrointestinal endoscopy technology, a mechanistically related but clinically distinct application. Investors and device developers evaluating early-stage robotic gastrointestinal endoscopy technology use robotic bronchoscopy’s demonstrated adoption trajectory as a concrete reference case for how quickly a genuinely novel robot-assisted navigation technology can move from early clinical use into mainstream procedural adoption, and this reference case directly lowers the perceived commercial risk of continued gastrointestinal robotic endoscopy investment, so bronchoscopy’s validated success and gastrointestinal robotic endoscopy investment activity are directly linked. Magnetically controlled capsule endoscopes and tethered robotic colonoscopy platforms remain in earlier-stage development and adoption relative to robotic bronchoscopy, but continued investment in these categories reflects growing confidence, informed directly by bronchoscopy’s adoption trajectory, that robot-assisted endoscopic navigation technology broadly can achieve mainstream clinical adoption. The effect on the market is that robotic gastrointestinal endoscopy development is proceeding with a clearer commercial reference case than it would have without robotic bronchoscopy’s established precedent. These are some of the key factors driving revenue growth of the market.

“Ion endoluminal procedure volume grew approximately 44% in the fourth quarter of 2025, nearly three times the approximately 17% growth rate recorded for da Vinci surgical procedures, establishing robotic bronchoscopy as the most commercially validated robot-assisted endoscope category and the reference case that developers of early-stage robotic gastrointestinal endoscopy technology now build their commercial case around.”

The third driver is the genuine patient experience and clinical access improvement that robotic gastrointestinal endoscopy technology offers relative to conventional flexible endoscopy technique. Conventional flexible colonoscopy and capsule endoscopy each carry known patient comfort and tissue access limitations, and magnetically controlled capsule endoscopes and tethered robotic colonoscopy platforms are specifically designed to address these limitations through improved manoeuvrability and reduced patient discomfort, so these clinical and patient experience limitations of conventional technique directly motivate continued robotic gastrointestinal endoscopy development investment. Magnetically controlled capsule endoscopes and tethered robotic colonoscopy platforms offer improved patient comfort and tissue access compared to conventional flexible endoscopy, directly addressing patient experience factors that influence screening and diagnostic procedure completion rates. The effect on the market is that robotic gastrointestinal endoscopy adoption, once clinical evidence and commercial availability mature further, has a genuine patient experience value proposition beyond diagnostic capability alone. These are some of the key factors driving revenue growth of the market.

However, the robot-assisted endoscope market faces adoption constraints from capital cost barriers for robotic endoscopy system adoption at community gastroenterology and pulmonology practices, incremental disposable cost per procedure above conventional endoscope reprocessing cost, and early-stage clinical evidence maturity for gastrointestinal applications specifically. Because robotic endoscopy systems, whether bronchoscopy or gastrointestinal platforms, represent a substantial capital investment beyond conventional flexible endoscopy equipment, community gastroenterology and pulmonology practices outside academic medical centres and high-volume procedural programmes face a genuine capital barrier that concentrates adoption among the largest, best-resourced practices, meaning the procedure volume growth robotic bronchoscopy has demonstrated remains concentrated at a specific tier of clinical practice rather than distributed broadly. Incremental disposable cost per procedure is a second constraint, because robotic endoscopy procedures typically carry a higher disposable cost than conventional endoscope reprocessing, and this per-procedure cost differential affects the economics of high-volume community practice adoption specifically, even where capital equipment cost has been addressed through leasing or other financing arrangements, meaning total cost of ownership analysis extends well beyond the initial capital purchase decision. Early-stage clinical evidence maturity for gastrointestinal applications is the third constraint, since magnetically controlled capsule endoscopes and tethered robotic colonoscopy platforms have not yet accumulated the multi-year clinical evidence base and procedure volume track record that robotic bronchoscopy has established, meaning gastrointestinal robot-assisted endoscopy adoption still depends on this evidence base maturing further before it can realistically approach bronchoscopy’s demonstrated adoption trajectory. These factors substantially limit robot-assisted endoscope market growth over the forecast period.

Based on product type, the global robot-assisted endoscope market is segmented into robotic bronchoscopy platforms, magnetically controlled capsule endoscopes, and tethered robotic colonoscopy systems. Robotic bronchoscopy platforms hold the largest revenue share, because they represent the only commercially mature category with an established, multi-year clinical adoption track record, which suits Intuitive Surgical’s and Johnson & Johnson’s dominant position in this specific application. Tethered robotic colonoscopy systems are expected to register rapid revenue growth in the global robot-assisted endoscope market over the forecast period, driven by continued clinical evidence development building on robotic bronchoscopy’s established adoption precedent, which is why this category represents an increasingly active area of development investment despite its current early stage.

Peripheral lung lesion navigation and biopsy application is expected to account for the largest revenue share in the global robot-assisted endoscope market during the forecast period

Based on application, the global robot-assisted endoscope market is segmented into peripheral lung lesion navigation and biopsy and gastrointestinal diagnostic endoscopy. Peripheral lung lesion navigation and biopsy holds the largest revenue share, directly reflecting robotic bronchoscopy’s established commercial maturity and its direct link to expanding lung cancer screening programme volume. Gastrointestinal diagnostic endoscopy is expected to register the fastest revenue growth rate in the global robot-assisted endoscope market over the forecast period, driven by continued magnetically controlled capsule endoscope and tethered robotic colonoscopy platform development, which is why this application represents the newest frontier of robot-assisted endoscope technology expansion.

Based on end-use, the global robot-assisted endoscope market is segmented into academic medical centres and community gastroenterology and pulmonology practices. Academic medical centres hold the largest revenue share, reflecting their capital capacity to absorb robotic endoscopy system cost and their role as early clinical evidence generation sites for newer applications such as robotic gastrointestinal endoscopy. Community gastroenterology and pulmonology practices represent a smaller but growing revenue category, with adoption pace directly constrained by capital cost barriers and incremental disposable cost per procedure relative to conventional endoscope reprocessing.

Based on regional analysis, the robot-assisted endoscope market in North America accounted for largest revenue share in 2025. The United States leads because it hosts the largest concentration of lung cancer screening programmes and academic medical centres pursuing early-stage robotic gastrointestinal endoscopy clinical development, and because Intuitive Surgical and Johnson & Johnson both concentrate significant commercial activity in the country. The scale of United States lung cancer screening programme infrastructure directly sustains the robotic bronchoscopy procedure volume base that anchors the broader robot-assisted endoscope market. The concentration of leading robot-assisted endoscope manufacturers and academic clinical development sites in the United States also means new robotic gastrointestinal endoscopy technology is typically first evaluated clinically in the United States.

The market in Europe is expected to register a steady revenue growth rate over the forecast period. Germany, the United Kingdom, and France represent the three largest national robot-assisted endoscope markets within Europe. The region’s established interventional pulmonology infrastructure and CE-marking regulatory pathway under the Medical Device Regulation sustain steady robotic bronchoscopy demand. The result is steady rather than rapid growth, shaped more by the region’s already-mature interventional pulmonology infrastructure than by the earlier-stage gastrointestinal robotic endoscopy development activity still concentrated primarily in the United States.

The market in Asia Pacific is expected to register a rapid revenue growth rate over the forecast period. China, Japan, and South Korea represent the three largest national robot-assisted endoscope markets within the region. Expanding lung cancer screening programme investment and rising interventional pulmonology infrastructure investment in China are driving new robotic bronchoscopy demand from a comparatively lower installed base, leaving more room for growth than in the already-mature North America market.

The market in Latin America is expected to register a moderate revenue growth rate over the forecast period. Brazil and Mexico represent the two largest national robot-assisted endoscope markets within the region. Academic pulmonology programmes in both countries are gradually adopting robotic bronchoscopy technology, and the indirect effects of Iran-US sanctions and the associated Strait of Hormuz shipping disruption have kept freight and import costs elevated for the specialised robotic endoscopy platforms that Latin American academic centres depend on through 2026, slowing adoption beyond the region’s main urban centres.

The market in Middle East and Africa is expected to register a moderate revenue growth rate over the forecast period. Saudi Arabia and the UAE represent the primary commercial robot-assisted endoscope markets within the GCC. The UAE is the most established robot-assisted endoscope market on the continent given its concentrated private hospital interventional infrastructure, while the wider Gulf states and broader African markets are still building the specialist pulmonology and gastroenterology capacity that robot-assisted endoscope adoption depends on.